BioMonde (Zoobiotic Limited and BioMonde GmbH) are manufacturers of Larval Therapy products, which are supplied to hospitals and pharmacies across the UK and Europe. BioMonde operate two manufacturing facilities, with a head office based in Bridgend, South Wales, and a sister site in Barsbüttel, Germany.
Established in 2005 as a commercial spinout from the NHS, BioMonde harnesses care and compassion at the heart of its business – putting the needs of patients and clinicians first, whilst supplying high quality products to ensure successful wound debridement outcomes.
Larval Therapy was reintroduced in the 1990s as a strategy to combat antimicrobial resistance and provide a safe alternative to antibiotics. Numerous studies have proven Larval Therapy to be a suitable treatment option for most non-healing and infected wounds such as diabetic foot ulcers, pressure ulcers, leg ulcers, burns and haematoma. By secreting proteolytic enzymes, larvae debride wounds by liquefying and ingesting devitalised tissue on a wound bed. As larvae do not have teeth, they use their mandibles and bodies to loosen and score any unviable tissue, to speed up the rate of tissue breakdown.
Larval secretions have been studied with interest over the last decade as they have been found to contain anti-inflammatory, antimicrobial, and antifungal properties, as well as the ability to stimulate fibroblast migration and angiogenesis, two factors essential in wound healing. Studies undertaken on larvae in leg ulcers and diabetic ulcers have shown faster debridement times, reduced amputation rates and fewer antibiotics being prescribed. Larvae have been shown to eradicate MRSA from wounds as well as common wound infections such as Pseudomonas aeruginosa and Staphylococcus aureus. Larvae can also remove complex biofilm within 48 hours and their secretions have been shown to prevent biofilm reformation.
The life cycle of the green bottle fly, Lucila sericata is very predictable. Larvae are able to debride a wound in up to four days of treatment. This rapid debridement time has the potential to provide healthcare providers clinical and financial benefits, such as reduced nursing hours, lower infection rates than other debridement methods and decreased hospital admissions. The simple application process of BioBag means that clinicians of any skill-level can use larvae, and is suitable for use in both acute and community settings.
BioMonde ensure that the Larval Therapy products we provide are of the highest possible standard. We operate a rigorous production process in an aseptic cleanroom environment and follow strict procedures at every level of our organisation. BioMonde are dedicated to supporting customers to ensure that the Larval Therapy products are used optimally, and a successful debridement outcome is secured. BioMonde deliver multi-layered Clinical Support to our customers, from training to educational online webinars, we ensure that clinicians are as confident and passionate about using Larval Therapy as they possibly can be.
For comments, images, and other press enquiries contact Stefan Docherty, Marketing Manager at BioMonde via email@example.com.